At ASPHALION, we provide Medical & Scientific Writing and Regulatory Affairs support to pharmaceutical and biotechnology companies throughout the development of Orphan Drugs. Our expertise includes the preparation of orphan designation applications, Scientific Advice and Protocol Assistance briefing packages, Paediatric Investigational Plans, clinical and regulatory documents, responses to health authorities, and other key regulatory submissions.
Although both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) offer incentives to encourage orphan drug development, their regulatory frameworks could differ significantly.
By combining scientific expertise with regulatory insight, our team prepares clear, accurate, and compliant documentation that supports successful interactions with regulatory authorities and helps streamline the development pathway.
Whether you are preparing an Orphan Drug Designation application to EMA and/or FDA, seeking scientific meetings with agencies, or advancing your clinical development program, we are ready to support you with tailored joint Medical Writing and Regulatory Affairs solutions.
Together, we help transform scientific innovation into life-changing therapies for patients living with rare diseases.
Contact us: [email protected]
